1. Severe spruelike enteropathy associated with olmesartan;Rubio-Tapia;Mayo Clin Proc,2012
2. Research C for DE and. Drug safety and availability - FDA drug safety communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm
3. ANSM. Cas graves d’entéropathies associés avec l’olmésartan médoxomil - Point d’information - ANSM. Agence nationale de sécurité du médicament et des produits de santé 2013. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Cas-graves-d-enteropathies-associes-avec-l-olmesartan-medoxomil-Point-d-information
4. Olmesartan-associated sprue-like enteropathy;Stanich;J Clin Gastroenterol,2013
5. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma;DeGaetani;Am J Gastroenterol,2013